Cargando…
Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate
Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6, is indicated for metastatic breast cancer treatment. Reversible increases in serum creatinine levels of ~15–40% over baseline have been observed following abemaciclib dosing. This study assessed the in vitro and clinical inhibition of re...
Autores principales: | Chappell, Jill C., Turner, P. Kellie, Pak, Y. Anne, Bacon, James, Chiang, Alan Y., Royalty, Jane, Hall, Stephen D., Kulanthaivel, Palaniappan, Bonventre, Joseph V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465099/ https://www.ncbi.nlm.nih.gov/pubmed/30449032 http://dx.doi.org/10.1002/cpt.1296 |
Ejemplares similares
-
Abemaciclib does not increase the corrected QT interval in healthy participants
por: Chappell, Jill C., et al.
Publicado: (2023) -
Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling
por: Posada, Maria M., et al.
Publicado: (2020) -
A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients
por: Tate, Sonya C., et al.
Publicado: (2017) -
Mechanisms of Glomerular Albumin Filtration and Tubular Reabsorption
por: Tojo, Akihiro, et al.
Publicado: (2012) -
Tubular Secretion Markers, Glomerular Filtration Rate, Effective Renal Plasma Flow, and Filtration Fraction in Healthy Adolescents
por: Seegmiller, Jesse C., et al.
Publicado: (2020)